Artal Group S.A.

In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 13, 2025), Artal Group S.A. reported 2 stock positions worth $930.2 million. Its top holding was Cava (CAVA) at 86.1% of the portfolio, followed by Lexicon Pharmaceuticals (LXRX, 13.9%). Its holdings were unchanged from Q1 2025.

Most Recent 13F
Q2 2026
Location
LUXEMBOURG, N4
CIK
0001053906
Portfolio Value
$930.2M (Q2 2025)
SEC Filing
0002005369-25-000020 ↗ filed Aug 13, 2025

Holdings Value

0$1.0B$2.0B$3.0B$4.0B Q1 2024: $3.9B Q1 2024 Q2 2024: $3.9B Q2 2024 Q3 2024: $2.4B Q3 2024 Q4 2024: $1.2B Q4 2024 Q1 2025: $884.2M Q1 2025 Q2 2025: $930.2M $930.2M Q2 2025 Q3 2025: $758.2M Q3 2025 Q4 2025: $714.6M Q4 2025 Q1 2026: $1.0B Q1 2026 Q2 2026: $931.1M Q2 2026

Holdings 2 stocks · $930.2M
CAVA Cava Group Inc. 86.09% 9,507,990 $800.9M No change
LXRX Lexicon Pharmaceuticals Inc. 13.91% 136,180,481 $129.4M No change

Portfolio Sells Q1 2025 → Q2 2025
None this quarter.

Portfolio Buys Q1 2025 → Q2 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$931.1MCAVA, LXRX
Q1 2026 2$1.0BCAVA, LXRX
Q4 2025 2$714.6MCAVA, LXRX
Q3 2025 2$758.2MCAVA, LXRX
Q2 2025 2$930.2MCAVA, LXRX
Q1 2025 2$884.2MCAVA, LXRX
Q4 2024 2$1.2BCAVA, LXRX
Q3 2024 2$2.4BCAVA, LXRX
Q2 2024 108$3.9BCAVA, LXRX, SRRK, KYMR, MORF
Q1 2024Amended 107$3.9BCAVA, LXRX, SRRK, KYMR, ARWR